ProfileGDS5678 / 1420499_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 83% 79% 78% 82% 73% 77% 73% 72% 78% 82% 80% 80% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5906380
GSM967853U87-EV human glioblastoma xenograft - Control 26.1866283
GSM967854U87-EV human glioblastoma xenograft - Control 35.5385679
GSM967855U87-EV human glioblastoma xenograft - Control 45.5840578
GSM967856U87-EV human glioblastoma xenograft - Control 56.0281782
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6316873
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.0706577
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6583773
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6280272
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4610678
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.947582
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.725980
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6021580
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0668383